• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Time to fellow eye involvement in patients with unilateral diabetic macular oedema.单侧糖尿病黄斑水肿患者的随访眼内情况。
Eye (Lond). 2023 Sep;37(13):2761-2767. doi: 10.1038/s41433-023-02410-5. Epub 2023 Feb 3.
2
Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy.光学相干断层扫描(OCT)用于检测糖尿病视网膜病变患者的黄斑水肿。
Cochrane Database Syst Rev. 2015 Jan 7;1(1):CD008081. doi: 10.1002/14651858.CD008081.pub3.
3
Monotherapy laser photocoagulation for diabetic macular oedema.糖尿病性黄斑水肿的单药激光光凝治疗
Cochrane Database Syst Rev. 2018 Oct 15;10(10):CD010859. doi: 10.1002/14651858.CD010859.pub2.
4
Anti-vascular endothelial growth factor for diabetic macular oedema.抗血管内皮生长因子治疗糖尿病性黄斑水肿
Cochrane Database Syst Rev. 2014 Oct 24(10):CD007419. doi: 10.1002/14651858.CD007419.pub4.
5
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.抗血管内皮生长因子治疗糖尿病性黄斑水肿:一项网状Meta分析。
Cochrane Database Syst Rev. 2018 Oct 16;10(10):CD007419. doi: 10.1002/14651858.CD007419.pub6.
6
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.抗血管内皮生长因子治疗糖尿病性黄斑水肿:一项网状Meta分析。
Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD007419. doi: 10.1002/14651858.CD007419.pub5.
7
The UK Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group, Report 2: real-world data for the impact of cataract surgery on diabetic macular oedema.英国糖尿病视网膜病变电子病历(UK DR EMR)用户组,报告2:白内障手术对糖尿病性黄斑水肿影响的真实世界数据。
Br J Ophthalmol. 2017 Dec;101(12):1673-1678. doi: 10.1136/bjophthalmol-2016-309838. Epub 2017 May 9.
8
Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy.光学相干断层扫描(OCT)用于检测糖尿病视网膜病变患者的黄斑水肿。
Cochrane Database Syst Rev. 2011 Jul 6(7):CD008081. doi: 10.1002/14651858.CD008081.pub2.
9
Real-world management of treatment-naïve diabetic macular oedema: 2-year visual outcome focusing on the starting year of intervention .初治糖尿病性黄斑水肿的真实世界管理:关注干预起始年份的 2 年视觉结局。
Br J Ophthalmol. 2020 Dec;104(12):1755-1761. doi: 10.1136/bjophthalmol-2019-315726. Epub 2020 Mar 13.
10
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.抗血管内皮生长因子治疗糖尿病性黄斑水肿:一项网状Meta分析。
Cochrane Database Syst Rev. 2023 Jun 27;2023(6):CD007419. doi: 10.1002/14651858.CD007419.pub7.

引用本文的文献

1
Interocular Symmetry of Choroidal Parameters in Patients with Diabetic Retinopathy with and without Diabetic Macular Edema.患有和未患有糖尿病性黄斑水肿的糖尿病视网膜病变患者脉络膜参数的眼内对称性
J Clin Med. 2023 Dec 28;13(1):176. doi: 10.3390/jcm13010176.

本文引用的文献

1
Progression to Vision-Threatening Retinopathy Complications Following Panretinal Laser for Proliferative Diabetic Retinopathy.增殖性糖尿病视网膜病变行全视网膜激光光凝后进展为威胁视力的视网膜病变并发症。
Ophthalmic Surg Lasers Imaging Retina. 2022 Apr;53(4):186-193. doi: 10.3928/23258160-20220316-03. Epub 2022 Apr 1.
2
Guidelines for the Management of Center-Involving Diabetic Macular Edema: Treatment Options and Patient Monitorization.《累及黄斑中心凹的糖尿病性黄斑水肿管理指南:治疗选择与患者监测》
Clin Ophthalmol. 2021 Jul 30;15:3221-3230. doi: 10.2147/OPTH.S318026. eCollection 2021.
3
Follow-Up Appointment Delay in Diabetic Macular Edema Patients.糖尿病性黄斑水肿患者的随访预约延误。
Ophthalmic Surg Lasers Imaging Retina. 2021 Apr;52(4):200-206. doi: 10.3928/23258160-20210330-04. Epub 2021 Apr 1.
4
Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy: The EMERALD Study.评估一种新的糖尿病视网膜病变并发症患者护理模式:EMERALD 研究。
Ophthalmology. 2021 Apr;128(4):561-573. doi: 10.1016/j.ophtha.2020.10.030. Epub 2020 Oct 31.
5
Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema.影响印度视网膜静脉阻塞、年龄相关性黄斑变性和糖尿病性黄斑水肿患者接受玻璃体内抗血管内皮生长因子治疗依从性的因素。
Indian J Ophthalmol. 2020 Oct;68(10):2143-2147. doi: 10.4103/ijo.IJO_1866_19.
6
The fellow eye effect of unilateral intravitreal conbercept injections in eyes with diabetic macular edema.糖尿病黄斑水肿患眼接受单眼玻璃体内康柏西普注射的对侧眼效应。
Acta Diabetol. 2020 Aug;57(8):1001-1007. doi: 10.1007/s00592-020-01511-x. Epub 2020 Mar 25.
7
Management of diabetic macular oedema: new insights and global implications of DRCR protocol V.糖尿病性黄斑水肿的管理:糖尿病性视网膜病变临床研究网络(DRCR)方案V的新见解及全球影响
Eye (Lond). 2020 Jun;34(6):999-1002. doi: 10.1038/s41433-019-0738-y. Epub 2019 Dec 16.
8
Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial.随机接受阿柏西普、贝伐单抗或雷珠单抗治疗的糖尿病性黄斑水肿患者在治疗期间视力变化与中心子野厚度变化之间的关联:Protocol T随机临床试验的事后分析
JAMA Ophthalmol. 2019 Sep 1;137(9):977-985. doi: 10.1001/jamaophthalmol.2019.1963.
9
Diabetic macular edema: Evidence-based management.糖尿病性黄斑水肿:循证管理。
Indian J Ophthalmol. 2018 Dec;66(12):1736-1750. doi: 10.4103/ijo.IJO_1240_18.
10
Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.玻璃体腔内阿柏西普治疗糖尿病性黄斑水肿:VISTA 和 VIVID 研究的 148 周结果。
Ophthalmology. 2016 Nov;123(11):2376-2385. doi: 10.1016/j.ophtha.2016.07.032. Epub 2016 Sep 17.

单侧糖尿病黄斑水肿患者的随访眼内情况。

Time to fellow eye involvement in patients with unilateral diabetic macular oedema.

机构信息

Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.

Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.

出版信息

Eye (Lond). 2023 Sep;37(13):2761-2767. doi: 10.1038/s41433-023-02410-5. Epub 2023 Feb 3.

DOI:10.1038/s41433-023-02410-5
PMID:36732545
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10482824/
Abstract

OBJECTIVE

To examine the time to onset of disease in the fellow eye of patients with unilateral DMO in routine clinical practice and to identify risk factors for development of bilateral DMO.

DESIGN

Retrospective cohort study.

PARTICIPANTS

One hundred forty treatment-naive patients 18 years or older with unilateral DMO presenting to Cole Eye Institute between January 2012 and July 2021.

METHODS

Records of patients with unilateral DMO were reviewed for development of DMO in the fellow eye. Demographic, diabetic, ocular, and systemic characteristics were collected at initial DMO diagnosis date. Bivariate and multivariate analyses were performed and significant factors were modelled using Kaplan-Meier curves.

RESULTS

Fifty patients with conversion to bilateral DMO and 90 patients without conversion were identified. Average time to bilateral DMO was 15.0 ± 15.7 months. 64% of patients converted within 1 year and 90% converted within 3 years. HbA1c (p = 0.003), diabetic retinopathy duration (p = 0.029), and diabetic foot disease (DFD) (p = 0.002) were identified as significant risk factors for conversion. Patients with better visual acuity at time of initial diagnosis and history of panretinal photocoagulation (PRP) (p = 0.044) or focal laser (p = 0.035) in the primary eye were also more likely to convert.

CONCLUSIONS

Participants were most likely to develop fellow eye DMO within the first year after initial DMO diagnosis. In routine clinical practice, poor glycaemic control and DFD were risk factors associated with bilateral eye involvement. Clinicians may consider screening the fellow eye of high-risk individuals at each appointment within the first year of diagnosis.

摘要

目的

在常规临床实践中,检查单侧 DMO 患者对侧眼的发病时间,并确定双眼 DMO 发生的危险因素。

设计

回顾性队列研究。

参与者

2012 年 1 月至 2021 年 7 月期间,Cole Eye Institute 就诊的 140 例未经治疗的单侧 DMO 且年龄在 18 岁或以上的初治患者。

方法

对单侧 DMO 患者的记录进行回顾性分析,以确定对侧眼 DMO 的发生情况。在初次 DMO 诊断日期时收集患者的人口统计学、糖尿病、眼部和全身特征。进行了单变量和多变量分析,并使用 Kaplan-Meier 曲线对显著因素进行建模。

结果

确定了 50 例双侧 DMO 转化患者和 90 例未转化患者。双侧 DMO 的平均发病时间为 15.0±15.7 个月。64%的患者在 1 年内转化,90%的患者在 3 年内转化。糖化血红蛋白(HbA1c)(p=0.003)、糖尿病视网膜病变持续时间(p=0.029)和糖尿病足病(DFD)(p=0.002)被确定为转化的显著危险因素。初次诊断时视力较好且原发性眼中曾接受全视网膜光凝术(PRP)(p=0.044)或局灶性激光治疗(p=0.035)的患者也更有可能发生转化。

结论

患者在初次 DMO 诊断后,最有可能在 1 年内发生对侧眼 DMO。在常规临床实践中,血糖控制不佳和 DFD 是与双眼受累相关的危险因素。临床医生可能会考虑在初次诊断后的第 1 年内,每次就诊时对高危人群的对侧眼进行筛查。